Kymera Therapeutics (KYMR) Payables: 2019-2025
Historic Payables for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $5.5 million.
- Kymera Therapeutics' Payables fell 15.21% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.5 million, marking a year-over-year increase of 2.41%. This contributed to the annual value of $6.0 million for FY2024, which is 15.35% down from last year.
- Latest data reveals that Kymera Therapeutics reported Payables of $5.5 million as of Q3 2025, which was down 4.76% from $5.8 million recorded in Q2 2025.
- Kymera Therapeutics' 5-year Payables high stood at $10.3 million for Q1 2025, and its period low was $2.4 million during Q2 2022.
- Over the past 3 years, Kymera Therapeutics' median Payables value was $6.5 million (recorded in 2023), while the average stood at $6.3 million.
- In the last 5 years, Kymera Therapeutics' Payables slumped by 70.97% in 2022 and then soared by 152.55% in 2023.
- Kymera Therapeutics' Payables (Quarterly) stood at $4.0 million in 2021, then climbed by 8.24% to $4.3 million in 2022, then skyrocketed by 63.21% to $7.1 million in 2023, then declined by 15.35% to $6.0 million in 2024, then declined by 15.21% to $5.5 million in 2025.
- Its Payables stands at $5.5 million for Q3 2025, versus $5.8 million for Q2 2025 and $10.3 million for Q1 2025.